Medpace (MEDP) Stock Looks Fully Valued After A 210% Run

Medpace Holdings has delivered strong long term share gains, which puts a spotlight on whether the current US$598.08 price is fully supported by the cash the business can generate. With the focus on its cash flows rather than headlines, the valuation question now matters more than ever for new money going into the stock.

• The share price has returned 209.6% over 5 years, which raises the stakes on whether that long run is aligned with the cash the company is expected to produce.
• A contract research model that tends to convert a high portion of revenue into cash can support a richer valuation, since predictable client work may translate into steadier future cash flows.
• What if you looked at Medpace Holdings through its earnings instead? See why Medpace Holdings's 34.0x P/E tells a different valuation story.

For investors, the debate is whether Medpace Holdings' recent share performance is justified by its intrinsic value when measured against the cash flows it is expected to generate over time.

If you want to test whether Medpace Holdings' cash flow based valuation question shows up elsewhere in the market, compare it with a curated list of 28 high quality undervalued stocks.

Where Does Medpace Holdings Sit on Cash Flow?

The Discounted Cash Flow model here is built around Medpace Holdings' ability to keep turning its contract research work into steady cash generation. Over the last twelve months the group produced roughly $706.3 million of free cash flow, which is a sizeable base for a company in this line of work and reflects a business that is already throwing off cash rather than relying only on distant projections.

Analysts see those cash flows continuing to grow, with forecasts pointing to higher annual free cash flow by 2030 rather than a shrinking stream. When those projected cash figures are discounted back and compared with the current share price of $598.08, the DCF output suggests Medpace Holdings' estimated intrinsic value is broadly in line with where the stock trades today, so the market price already reflects much of the cash flow story. Find out what Medpace Holdings could be worth using our Discounted Cash Flow (DCF) estimate.

The Medpace Holdings Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where that cash flow puzzle for Medpace Holdings leaves off. They map out what would need to change in Medpace Holdings' growth path, profitability and earnings power for the shares to look meaningfully richer or cheaper than today. Each one ties its figure to a clear view on how growth, margins and risk might evolve, giving you something concrete to revisit as fresh information comes through.

The community is split on Medpace Holdings, with one side leaning into bookings strength and the other focused on how much optimism is already in the price.

Bull case: 14% undervalued

"Analysts broadly agree that improving book-to-bill ratios above 1.15x will support backlog growth, but the current environment of sharply lower cancellations and clients quickly securing adequate funding could drive a supercycle of booking acceleration…"

Discover why this Narrative puts Medpace Holdings at 14% undervalued.

Bear case: 12% overvalued

"That multiple does not prove the stock is overvalued, but it does show that investors are already paying for durable double-digit growth and stable margins…"

Explore why this Narrative puts Medpace Holdings at 12% overvalued.

The Medpace Holdings story is not complete without one more check

One final thread matters for anyone weighing Medpace Holdings, since recent director and executive share sales have been flagged and the individuals involved, the dollar amounts and what they might signal are still for you to review. See the recent insider selling flagged for Medpace Holdings.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com